TriSalus Life Sciences (TLSI) EBT Margin (2022 - 2026)

TriSalus Life Sciences' EBT Margin history runs 5 years deep, the most recent figure standing at 17.34% for Q1 2026.

• On a quarterly basis, EBT Margin rose 13046.0% year-over-year to 17.34% in Q1 2026; TTM through Mar 2026 was 60.84%, a 2381.0% increase from a year earlier, with the FY2025 full-year figure at 86.86%, up 1520.0% from the prior year.
• EBT Margin rose to 17.34% in Q1 2026 per TLSI's latest filing, from 73.86% in the prior quarter.
• Across five years, EBT Margin topped out at 17.34% in Q1 2026 and bottomed at 698.57% in Q4 2022.
• The 5-year median for EBT Margin is 113.12% (2025), against an average of 192.7%.
• Across the five-year window, EBT Margin surged 50056 bps in 2024 and plunged 6074 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 698.57% in 2022, then gained by 11 bps to 622.93% in 2023, then soared by 80 bps to 122.37% in 2024, then surged by 40 bps to 73.86% in 2025, then jumped by 123 bps to 17.34% in 2026.
• Per Business Quant, the three latest TLSI EBT Margin figures stand at 17.34% (Q1 2026), 73.86% (Q4 2025), and 93.43% (Q3 2025).